DE60322884D1 - Pathogene impstoffe und verfahren zur deren verwendung - Google Patents
Pathogene impstoffe und verfahren zur deren verwendungInfo
- Publication number
- DE60322884D1 DE60322884D1 DE60322884T DE60322884T DE60322884D1 DE 60322884 D1 DE60322884 D1 DE 60322884D1 DE 60322884 T DE60322884 T DE 60322884T DE 60322884 T DE60322884 T DE 60322884T DE 60322884 D1 DE60322884 D1 DE 60322884D1
- Authority
- DE
- Germany
- Prior art keywords
- vaccines
- antigen
- lna
- ifn
- pathogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000001717 pathogenic effect Effects 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 239000002245 particle Substances 0.000 abstract 3
- 244000052769 pathogen Species 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 102100037850 Interferon gamma Human genes 0.000 abstract 2
- 108010074328 Interferon-gamma Proteins 0.000 abstract 2
- 230000008348 humoral response Effects 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 230000002596 correlated effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 230000028996 humoral immune response Effects 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- -1 lipid nucleic acid Chemical class 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37934302P | 2002-05-10 | 2002-05-10 | |
| US10/290,545 US20030125292A1 (en) | 2001-11-07 | 2002-11-07 | Mucoscal vaccine and methods for using the same |
| US45429803P | 2003-03-12 | 2003-03-12 | |
| PCT/CA2003/000680 WO2003094829A2 (en) | 2002-05-10 | 2003-05-12 | Pathogen vaccines and methods for using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60322884D1 true DE60322884D1 (de) | 2008-09-25 |
Family
ID=29424456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60322884T Expired - Fee Related DE60322884D1 (de) | 2002-05-10 | 2003-05-12 | Pathogene impstoffe und verfahren zur deren verwendung |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1505942B1 (de) |
| JP (1) | JP2005525414A (de) |
| AT (1) | ATE404152T1 (de) |
| AU (1) | AU2003229435A1 (de) |
| CA (1) | CA2485256A1 (de) |
| DE (1) | DE60322884D1 (de) |
| WO (1) | WO2003094829A2 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| WO2005034979A2 (en) * | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| CA2560108A1 (en) * | 2004-04-02 | 2005-11-24 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing il-10 responses |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| CN108136206B (zh) | 2015-07-17 | 2021-10-15 | 阿克丘勒斯治疗公司 | 抗乙型肝炎病毒的组合物和药剂及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001015726A2 (en) * | 1999-08-27 | 2001-03-08 | Inex Pharmaceuticals Corp. | Compositions for stimulating cytokine secretion and inducing an immune response |
| US20030119774A1 (en) * | 2001-09-25 | 2003-06-26 | Marianna Foldvari | Compositions and methods for stimulating an immune response |
| US20030125292A1 (en) * | 2001-11-07 | 2003-07-03 | Sean Semple | Mucoscal vaccine and methods for using the same |
-
2003
- 2003-05-12 WO PCT/CA2003/000680 patent/WO2003094829A2/en not_active Ceased
- 2003-05-12 CA CA002485256A patent/CA2485256A1/en not_active Abandoned
- 2003-05-12 JP JP2004502918A patent/JP2005525414A/ja active Pending
- 2003-05-12 EP EP03722135A patent/EP1505942B1/de not_active Expired - Lifetime
- 2003-05-12 AU AU2003229435A patent/AU2003229435A1/en not_active Abandoned
- 2003-05-12 AT AT03722135T patent/ATE404152T1/de not_active IP Right Cessation
- 2003-05-12 DE DE60322884T patent/DE60322884D1/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE404152T1 (de) | 2008-08-15 |
| JP2005525414A (ja) | 2005-08-25 |
| EP1505942A2 (de) | 2005-02-16 |
| WO2003094829A2 (en) | 2003-11-20 |
| AU2003229435A1 (en) | 2003-11-11 |
| AU2003229435A8 (en) | 2003-11-11 |
| CA2485256A1 (en) | 2003-11-20 |
| WO2003094829A3 (en) | 2004-02-05 |
| EP1505942B1 (de) | 2008-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE494910T1 (de) | Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort | |
| WO2004026265A3 (en) | Compositions and methods for treatment of herpesvirus infections | |
| DE69929444D1 (de) | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung | |
| IL150602A (en) | Proteosome influenza vaccine, method for preparing such and use thereof | |
| WO2003059381A3 (en) | Immunogenic preparations and vaccines on the basis of mrna | |
| DE60234375D1 (de) | VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG | |
| TW200732346A (en) | Chimeric hepatitis C virus antigens for eliciting an immune response | |
| NZ545048A (en) | Chimeric antigens for breaking host tolerance to foreign antigens | |
| DE60335186D1 (de) | Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung | |
| WO2002056905A3 (en) | Molecular antigen array | |
| WO2007052058A8 (en) | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators | |
| EP1594536A4 (de) | Adjuvante influenza-vakzine | |
| MXPA01011660A (es) | Adyuvante optimizado en estabilidad y biocompatibilidad (sba) para aumentar la respuesta inmune humoral y celular. | |
| WO2004103269A3 (en) | Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia | |
| DE60322884D1 (de) | Pathogene impstoffe und verfahren zur deren verwendung | |
| WO2009074861A3 (en) | Improved vaccine | |
| WO2007016340A3 (en) | Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response | |
| WO2005012538A3 (en) | Accelerated vaccination | |
| WO2002053588A3 (en) | Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of chlamydia psittaci | |
| DE602004027940D1 (de) | Zusammensetzungen und verfahren zur aktivierung der eigenen und allergischen immunität | |
| WO2002062298A3 (en) | Pro-apoptotic bacterial vaccines to enhance cellular immune responses | |
| ATE494377T1 (de) | Vakzine gegen ipnv die aus hefezellen isoliert werden | |
| SE9903534D0 (sv) | Vaccin | |
| DE60335742D1 (de) | Zusammensetzungen mit antigen-komplexen,verfahren zu ihrer herstellung und verfahren zur verwendung derantigen-komplexe zur vakzinierung | |
| DK1227840T3 (da) | Adjuverede, genetiske vacciner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |